STOCK TITAN

Castle Biosciences Inc - CSTL STOCK NEWS

Welcome to our dedicated news page for Castle Biosciences (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Castle Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Castle Biosciences's position in the market.

Rhea-AI Summary
Castle Biosciences announces new data demonstrating the ability of the DecisionDx-SCC test to identify high-risk tumors in patients with low-risk staging for cutaneous squamous cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
-
Rhea-AI Summary
Castle Biosciences to present new data on DecisionDx-Melanoma and DecisionDx-UM at ASCO Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
Rhea-AI Summary
Castle Biosciences continues its collaboration with The Sun Bus and The Skin Cancer Foundation to support skin cancer prevention, research, education, and advocacy during Skin Cancer Awareness Month. The company emphasizes the importance of prevention, early detection, and optimized treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.31%
Tags
none
-
Rhea-AI Summary
Castle Biosciences opens new laboratory facility in Pittsburgh and plans to double its workforce in the city by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
none
-
Rhea-AI Summary
Castle Biosciences reports a 57% increase in Q1 2023 revenue compared to Q1 2022, reaching $42 million. The company also delivered a 73% increase in total test reports for the same period. Castle Biosciences reaffirms its full-year 2023 revenue guidance of $170-180 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
none
Castle Biosciences Inc

Nasdaq:CSTL

CSTL Rankings

CSTL Stock Data

553.40M
26.64M
4.28%
89.75%
5.22%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Friendswood

About CSTL

castle biosciences, inc. specializes in diagnostic tests for cancers. founded in 2008, the company goal has been to help advance the care for cancers through objective testing. our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. currently, castle biosciences has tests to help doctors treat cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma and glioma. we have active research programs in rectal cancer and soft tissue sarcoma, and anticipate tests for these and other under-served cancers to be available in the near future please visit us at www.castlebiosciences.com for more information on our company and products.